Diabetes mellitus (DM) is a group of metabolic diseases related to the dysfunction of insulin, causing hyperglycaemia and life-threatening complications. Current early screening and diagnostic tests for DM are based on changes in glucose levels and autoantibody detection. This review evaluates recent studies on biomarker candidates in diagnosing type 1, type 2 and gestational DM based on omics classification, whilst highlighting the relationship of these biomarkers with the development of diabetes, diagnostic accuracy, challenges and future prospects. In addition, it also focuses on possible non-invasive biomarker candidates besides common blood biomarkers.
Introduction
Diabetes mellitus (DM) is a group of metabolic diseases resulting in hyperglycaemic conditions. It is associated with defects in either insulin production, insulin action, or both [1] . As this disease progresses, it may lead to the dysfunction of various organs, most commonly the eyes, blood vessels, kidneys, heart, and nerves [1] . Globally, according to the World Health Organisation (WHO), the prevalence and incidence of diabetes has increased from 108 million in 1980 to 422 million in 2014 [2] . In the past decade, the International Diabetes Federation positions 13 (histidine and serine) and 71 (lysine), as well as HLA-DQβ1 position 57 (alanine) [36] . For HLA-DRβ1 point mutations, at position 13, histidine and serine are tagged for HLA-DR4 and HLA-DR3, respectively, while an SNP at position 71 (lysine) is tagged for both HLA-DR [36] .
Studies also show that SNPs in the MHC class I gene region of CD8 T cells remain major genetic risk determinants of T1D, but have linkage disequilibrium towards HLA-DR/DQ alleles. Interestingly, the HLA-C gene does not reflect linkage disequilibrium towards HLA-DR/DQ haplotypes [36] . Furthermore, using immunochip, a customised genotyping array, SNPs at non-MHC regions, as detected in the serum, were found to be associated with the production of these autoantibodies (Table 1) . Therefore, these loci could be used as candidates for early screening of T1D. Table 1 : Association between autoantibody production and single-nucleotide polymorphisms at non-major histocompatibility complex regions.
Autoantibodies
Locus References GADA IFIH1/2q24, 3q28/LPP [34] , [37] IA-2A IFIH1/2q24, PTPN22/1p13, BACH2/6q15, IL10/1q32, IFIH1/2q24, IL27/16p11, CTLA4/2q33, 1q23/FCRL3, 11q13/RELA [34] , [37] 21-OHA IFIH1/2q24, IL2/4q27 [34] , [37] PCA IFIH1/2q24, PTPN22/1p13, SH2B3/12q24, SKAP2/7p15, IL2RA/10p15, INS/11p15, UBASH3A/21q22, 2q24/IFIH1 [34] , [37] TPOA IFIH1/2q24, PTPN22/1p13, SH2B3/12q24, BACH2/6q15, CD69/12p13, ERBB3/12q13, SIRPG/20p13 [34] , [37] TGA CTLA4/2q33, 3q28/LPP [34] , [37] ZnT8A CTSH/15q25, 1q23/FCRL3 [34] , [37] GADA, Glutamic acid decarboxylase autoantibody; IA-2A, insulinoma-2-associated autoantibody; 21-OHA, 21-hydroxylase autoantibody; PCA, gastric parietal cell autoantibody; TPOA, thyroid peroxidase autoantibody; TGA, transglutaminase autoantibody; ZnT8A, zinc transporter 8 autoantibodies.
Type 2 and gestational diabetes mellitus
SNPs in gene regions are associated with the risk of T2D and GDM. According to the NHGRI-EBI catalog of published genome-wide association studies (GWAS), many genes have been reported to be highly-associated with T2D predisposition, while significantly less were reported to be associated with GDM predisposition. Given that pathophysiological similarities exist between T2D and GDM with common genetic origin, we review some of the genes that are highly-associated with T2D predisposition. The selected genes are: cyclin-dependent kinase 5 regulatory subunit associated protein 1-like 1 (CDKAL1); potassium voltage-gated channel subfamily Q member 1 (KCNQ1); and cyclin dependent kinase inhibitors 2A/B (CDKN2A/B). These genes, as well as their SNPs, are associated with the risk of both T2D and GDM [38] , [39] . Found to be expressed in both blood and diabetic targeted tissues [38] , these SNPs could serve as candidate blood-based biomarkers for T2D and GDM. SNPs of CDKAL1, a gene on chromosome region 6p22.3 [38] , are believed to be associated with impaired first phase insulin output in T2D and GDM [40] , [41] , [42] . Impaired cyclic adenosine monophosphate(cAMP)induced insulin output is seen in the CDKAL1 (−/−) human embryonic stem cells differentiated into pancreatic β-cells [43] , where the misreading of the Lys-coding codon in proinsulin reduces glucose-stimulated proinsulin synthesis whilst increasing endoplasmic reticulum stress [44] . CDKAL1 plays a critical role in biosynthesising a part of tRNA Lys and is required for the translation of Lys residues in proinsulin at the ribosome [44] . In terms of diabetic complications, SNPs of the CADKAL1 region are also linked to the risk of developing obesity [45] and diabetic retinopathy [46] but the pathophysiological processes have yet to be reported.
The KCNQ1 gene, located at chromosome 11p15.4 region [38] , encodes for a pore-forming α-subunit termed K v 7.1, which is a potassium voltage-gated (K v ) channel protein [47] , [48] . SNPs of the KCNQ1 region are hypothesised to be associated with impaired insulin secretion and glucose intolerance, but not the maturation of pancreatic β-cells for insulin production in T2D and GDM [42] , [43] , [47] . KCNQ1 mutations result in greater insulin output impairment than CDKAL1 mutations found in human embryonic stem cells that have been differentiated to pancreatic β-cells [43] . The KCNQ1 gene and its protein subunit has been known for its role in generating outward-rectifying K + current flow during the repolarisation and post-repolarisation phase in pancreatic β-cell action potentials, causing insulin and GLP-1 exocytosis from pancreatic β-cells and intestinal L-cells, respectively [48] , [49] , [50] . In terms of diabetic complications, SNPs of the KCNQ1 region are hypothesised to be associated with the risk of developing diabetic nephropathy and hypertension [51] , [52] .
The CDKN2A/B genes, located at the chromosome 9p21.3 region [38] , encode for three proteins: p16 inhibitors of cyclin dependent kinase 4 (p16 INK4A ), p14 alternative reading frame (p14 ARF ) and p15 inhibitors of cyclin dependent kinase 4 (p15 INK4B ) proteins [53] ; but only the p16 INK4A protein is seen to be expressed in pancreatic β-cells [54] , [55] , [56] . The CDKN2A/B genes and their proteins are known for their roles in controlling cell-cycle progression and influence tumorigenesis, senescence, and aging [53] . p16 INK4A protein expression in pancreatic β-cell inhibits its proliferation and regeneration, while possibly altering its function related to insulin secretion [54] , [55] . SNPs within the CDKN2A/B regions are hypothesised to be associated with a reduction in pancreatic β-cell mass, proliferation and function in T2D as well as GDM [39] , [57] . In terms of diabetic complications, SNPs of the CDKN2A/B region and mutations of its protein, p16 INK4A might be associated with a risk in developing obesity and cardiovascular disease [58] , [59] . Therefore, SNPs within these gene regions might serve as candidate biomarkers for T2D and GDM risks. However, these genes were not studied using genomics tools, hence more studies could be done on the association of the SNPs within these genes and the risk factors of T2D and GDM, they should be considered carefully before confirming them as candidates for risk biomarkers.
Transcriptomics
Transcriptomics focuses on examining total RNA profiles: coding and non-coding RNAs expressed in a cell or an organism. Transcriptomics, defined as the product in the cell or particular tissue that is transcribed from the genome, includes both the qualitative and quantitative study of RNAs present, as well as the functional roles of these RNAs, such as in structure and regulation [28] . The tools that are normally associated in this study include different types of RNA microarrays [60] and RNA sequencing [61] , which can also combine with polymerase chain reaction (PCR) technologies.
Type 1 diabetes mellitus
MicroRNA (miRNA) are small non-coding RNA which play an important role in gene regulation at the mRNA level by binding to mRNA, causing translational inhibition [62] . Each miRNA regulates different biological functions and is expressed differently in diseased-state compared to healthy individuals [63] . In pancreatic βcells, the major T1D autoantigens (IA-2, IA-2β, and GAD65) are regulated by miRNA (mostly from chromosomal location 14q32). Using quantitative real-time PCR (qRT-PCR) analysis, the overexpression of miR-665 was found to reduce the production of the IA-2 antigen, while overexpression of miR-342 reduced the production of not only the IA-2 but also the IA-2β antigens. Overexpression of miR-370 reduces expression of the GAD65 antigen [64] .
Recently, by using miRNA microarray, followed by qRT-PCR validation, a study showed that miRNA in the exosomes in blood plasma, such as miR-16-5p, miR-302d-3p, and miR-574-5p, were downregulated [65] and involved in the regulation of second phase insulin output. In addition, using qRT-PCR quantification followed by miRNA sequencing, or miRNA microarray, these miRNAs in peripheral blood mononuclear cells (PBMCs) have been found to be specific to T1D: let-7, miR-103, miR-1260, miR-1274, miR-130a, miR-150, miR-20b, miR-720, miR-193a-5p, miR-16-5p, miR-142-5p, miR-133a-3p, miR-409-5p, miR-1271-5p, miR-501-3p, miR-486-5p, miR-145-3p, and miR-3150-3p [66] , [67] , [68] . According to Massaro et al., miR-133a-3p is related to the T1D pathway [68] , while other miRs are associated with diabetic retinopathy and nephropathy [68] .
On the other hand, other miRNA such as, miR-375 and miR-21 play important roles in regulating cellular differentiation and apoptosis, respectively, of the β islet cells [69] , [70] , [71] . Urinary miR-126 correlates well with HbA 1c (R = −0.286) [69] and endothelial cell miR-126 are important in the development of retinopathy in diabetes, due to an increase in Spread-1 mRNA and protein levels, which in turn decrease endothelial progenitor cell colony formation, migration and proliferation [68] , [72] , [73] . However, these are not transcriptomics-based studies and researchers could look into it in the future.
The majority of miRNA is found in the plasma of T1D patients, while only a minority is found in other biological samples. As such, a possible correlation between plasma and urine miRNA associated to T1D is feasible. The upregulation or downregulation of miRNAs associated with T1D from different biological samples are listed in Table 2 . [67] , [68] , [69] , [71] , [74] , [75] , [76] Urine MiR-21a, MiR-210 MiR-126 [69] Type 2 diabetes mellitus Similar to T1D, miRNA associates with the gene expression of insulin-resistant genes in T2D. There are many miRNAs found in plasma, such as miR-7, which regulates blood glucose and triglyceride levels by acting as a negative regulator [77] , [78] . An overexpression of miR-7 reduces glucose-stimulated insulin secretion and pancreatic β-cell mass, and vice versa [78] . Another example is miR-802, which targets hepatocyte nuclear factor 1 β gene expression in liver cells [79] . Increasing miR-802 expression causes glucose intolerance, insulin resistance and stimulates hepatic gluconeogenesis [79] . Using qRT-PCR quantification followed by miRNA sequencing, or miRNA microarray, [66] , [68] other miRNAs in PBMC specifically found in T2D patients include miR-140-3p, miR-199a-3p, miR-222, miR-30e, miR-451, miR-181c-3p, miR-148a-5p, and miR-143-3p. According to Massaro et al., miR-181c-3p and miR-148a-5p are related to T2D pathway [68] . Still other miRNAs are associated with other diseases, such as miR-503 is downregulated in T2D and obesity [80] , while miR-126 is related to major cardiovascular events [81] . The miRNAs that are identified in the plasma of T2D patients are listed in Table 3 . [77] , [80] , [82] , [83] , [84] , [85] Besides blood, which is a common biological sample, saliva mRNA also serves as a biomarker to diagnose T2D. In saliva samples, by using transcriptomic diagnostics such as mRNA microarray, mRNAs of Kirsten rat sarcoma 2 viral oncogene homolog (KRAS), spermidine/spermine N1-acetyltransferase 1 (SAT1), solute carrier family 13, member 2 (SLC13A2), and transmembrane protein 72 (TMEM72) were found to be up-regulated, while mRNAs of epidermal growth factor receptor (EGFR) and proteasome subunit beta type-2 (PSMB2) were found to be downregulated in T2D patients [86] . The sensitivity and specificity of saliva mRNAs as potential diagnostic biomarkers for T2D are listed in Table 4 . Combining the detection of the mRNAs of KRAS, SAT1, EGFR, and PSMB2, sensitivity could increase to 100% and specificity to 77% [86] . This shows that saliva mRNA profiles may serve as non-invasive biomarkers to diagnose T2D as an alternative to blood samples. KRAS, K-Ras; SAT1, spearmidine/spermine N1-acetyltransferase 1; SLC13A2, solute carrier family 13, member 2; TMEM72, transmembrane protein 72; PSMB2, proteasome subunit beta type-2; EGRF, epidermal growth factor receptor.
Gestational diabetes mellitus
Several classes of non-coding RNA have a significant role in gene regulation at the transcription-translational level of GDM pathogenesis. However, to date, the majority of the non-coding RNAs identified in GDM are miR-NAs, which function by interfering with the translational process of mRNA [87] . Using RNA-sequencing (such as the Illumina HiSeq 250 platform), combined with qRT-PCR or microarrays (such as TaqMan miRNA array), or miRNA PCR array, most of the dysregulated miRNA activities are seen during the early second trimester of pregnancy of GDM patients [87] , [88] , [89] , [90] . Most of the miRNAs were upregulated and only a minority was downregulated in GDM throughout the whole gestational period. The changes in blood miRNAs that are associated with GDM (based on trimesters) are listed in Table 5 . Table 5 : Changes in blood microRNA associated with gestational diabetes mellitus.
Trimesters of pregnancy

Upregulation Downregulation References
Early second
- [88] , [89] Late second MiR-142, MiR-143, MiR-330-3p, MiR-340, MiR-142, MiR-let-7g
MiR-20a-5p, MiR-222-3p [87] , [89] , [90] Third MiR-143, MiR-340, MiR-let-7g MiR-20a-5p, MiR-222-3p [87] , [89] , [90] In the early second trimester of pregnancy, miRNAs associated with insulin resistance, such as miR-16-5p, miR-17-5p, miR-19a-3p, miR-19b-3p and miR-20a-5p were found to be increased in the sera of GDM patients compared to non-GDM persons [88] , [91] . However, the sensitivity of miR-16-5p, miR-17-5p and miR-20a-5p detection was only 41.6%, 21.4% and 17.8%, respectively; while specificity was 95.8%, 98.4% and 95.4%, respectively [91] . Interestingly, miR-20a-5p increased in the early second trimester of pregnancy but decreased in late second and third trimesters in GDM patients [88] , [90] . In mice, it was found that miR-17-5p levels decreased in diabetic mice compared to non-diabetic mice [92] . This is due to the high glucose level that activates apoptosis signal-regulating kinase 1 by suppressing miR-17, resulting in increased gene expression of thioredoxininteracting protein [92] . Lately, the dysregulation of plasma miR-155-5p, miR-21-3p, miR-146b-5p, miR-223-3p, miR-517-5p and miR-29a-3p levels was found to be related to GDM patients in their early-and mid-term pregnancies and having male foetuses [93] . However, although the dysregulation of these plasma miRNAs was not found based on transcriptomics diagnostic tools, their diagnostic values could be considered.
In the late second and third trimesters of GDM patients, serum miR-20a-5p, which has a role in controlling insulin signalling, is significant reduced [90] . Interestingly, serum miR-222-3p amounts is significantly decreased in GDM but increased in T1D [67] , [90] . On the other hand, a significant upregulation of miR-340 in the white blood cells of GDM patients is inversely associated with polyadenylate-binding protein-interacting protein 1 (PAIP1) levels [87] . According to Stirm et al., miR-340 expression changes with insulin and glucose levels in GDM by targeting PAIP1 gene expression [87] . However, there is a lack of functional studies of PAIP1 gene expression towards GDM. In addition to T2D, miR-143, which plays a part in mediating aerobic glycolysis, has been reported to marginally increase in GDM patients [87] , [94] . Its overexpression leads to increased mitochondrial respiration and protein expression of mitochondrial complexes, and decreased expression of glycolytic enzymes in GDM [94] . The miRNA let-7g, a key player in glucose metabolism and insulin sensitivity [87] , [95] was also found to be increased. In GDM, there is a genetic variation of rs3811463 (SNP near miR-let-7 binding site in Lin28). This may alter the level of miR-let-7 and affect glucose uptake, glucose metabolism and insulin sensitivity [95] . The discovery of miRNAs and their potential roles in GDM may improve current screening and diagnostic strategies in GDM as they could further facilitate improvements to the current understanding of pancreatic β-cells dysfunction in GDM. Compared to the current methods, miRNAs could help in giving an earlier detection of dysregulation in glucose and insulin and dysfunction of pancreatic β-cells leading to GDM.
Proteomics
Proteomics is a high-throughput analysis of peptide or protein abundance in a cell, body fluid, or organism, including their structure, functions, modifications and interaction with others [28] . It utilises tools such as protein arrays [96] combined with mass spectrometry technologies and other protein separation techniques [97] .
Type 1 diabetes mellitus
Although each autoantigen is regulated by miRNA, the production of autoantibodies by B-lymphocytes against these autoantigens is associated with some risk factors, such as age, gender and race. Up until now, the most common biomarkers in diagnosing T1D are islet autoantibodies (IA-2A, GADA, and ZnT8A) [34] , [37] . Laterage onset of T1D is related to GADA, TPOA and PCA, but not TGA [34] , [37] . In terms of having T1D duration, a shorter diabetic duration is found with GADA, IA-2A, ZnT8A, and TGA, but a longer duration is found with TPOA, PCA, and 21-OHA [34] , [37] . In terms of gender, female T1D patients are associated with GADA, TPOA, PCA, and TGA [34] , [37] . In terms of race, GADA is found more in African-Americans, while TGA is found in Native American [34] . The sensitivity and specificity of the three most common autoantibodies (ZnT8A, GAGA, and IA-2A) are listed in Table 6 . Due to these variations, the need for identifying other protein biomarkers for the diagnosis of T1D is crucial. Recently, using proteomics diagnostic tools, six novel T1D autoantibodies have been identified using nucleic acid programmable protein array [100] . These autoantibodies are against protein tyrosine phosphatase, receptor type N2 (PTPRN2), mutL homolog 1 (MLH1), peptidyl-prolyl cis-trans isomerase-like 2 (PPIL2), nucleoporin 50, pyroglutamylated RFamide peptide receptor (QRFPR) and mitochondrial translational initiation factor 3 (MTIF3), with sensitivities ranging from 16 to 27% and a specificity of 95% [100] . The combination of using anti-MLH1, -PTPRN2, -PPIL2, and -QRFPR showed that the sensitivity increased to 37.5% in diagnosing T1D [100] .
In addition to autoantibodies, serum adiposity proteins have been widely studied for their roles in T1D. It has been shown that several proteins, such as immune molecules and hormones, are linked to T1D. Although the validity of these proteins has yet to be determined through proteomics approach, they could be considered as the T1D biomarkers in future studies. The serum adiposity changes in T1D are listed in Table 7 . Table 7 : Changes in serum adiposity of type 1 diabetes.
Serum adiposity References Increases Decreases
Proinflammatory adipokines, visfatis, chemerin, adiponectin Anti-inflammatory adipokines, leptin, omentin [101] , [102] , [103] , [104] 
Type 2 diabetes mellitus
Even though ZnT8A, IA-2A, GADA and insulin autoantibody (IAA) are also found in both T1D and T2D patients' sera [105] , [106] , T2D patients very rarely develop autoantibodies [107] . In addition, GADA and ZnT8A contribute to the progression towards T2D complications, polyneuropathy and nephropathy [105] , while IAA and IA-2A are associated with obesity and overweightness in T2D complications [108] . Thus, these autoantibodies are not potential significant biomarkers in diagnosing T2D. Recently, a screening for potential serum proteomic biomarkers for T2D using matrix-assisted laser desorption/ionisation-mass spectrometry showed that fragments of complement C3f and kininogen 1 isoform 1 precursor are associated with T2D [109] , with an accuracy of 82.20%, sensitivity of 82.50% and specificity of 77.80% [109] . Moreover, using functional high-density protein microarray combined with the Luminex system, peroxisome proliferator-activated receptor gamma 2 (PPARG2) and NEDD8-conjugating enzyme Ubc12 (UBE2M) autoantibodies are found to be increased in T2D patients' sera (without HLA haplotype background HLA-DRβ1*02) compared to the normal control subjects (with HLA haplotype background) [110] . An individual having HLA-DRβ1*02 haplotype is protected from T2D as it is associated with increased insulin secretion as compared to an individual without the HLA haplo-type background [111] . PPARG2 has a sensitivity of 42%, specificity of 78% and accuracy of 60% while UBE2M has a sensitivity of 33%, specificity of 82% and accuracy of 58% [110] . Combining them had higher sensitivity (51%), specificity (82%) and accuracy (67%) [110] . The PPARG protein has previously been reported to be associated with obesity, cardiovascular disease and cancer [112] . A higher level of prefoldin subunit 2 antibody (PFDN2A) is found in T2D patients' sera (without HLA haplotype background HLA-DRβ1*02), which has not been previously associated with T2D [113] . Prefoldin is responsible for the proper folding of protein structure and preventing aggregation [114] , [115] . PFDN2A is more prevalent with early-age onset of T2D than late-onset [116] . Besides antibodies against islet antigens, other serum proteins could also serve as candidates for protein biomarkers of T2D. For example, leptin, retinol binding protein 4, pigment epithelium-derived factor and betatrophin levels are increased in T2D, whereas adiponectin and acute C-peptide levels are decreased [117] , [118] , [119] , [120] , [121] , [122] , [123] . Serum betatrophin is positively associated with blood pressure and serum fasting glucose and serves as a potential diagnostic biomarker for T2D as it shows a sensitivity of 83.56% and specificity of 72.41% [120] , [122] .
In addition to serum proteins, salivary proteins could be used as a diagnostic biomarker for T2D, although their levels are not as high as that of serum proteins [124] . A positive correlation of the proteins, such as αamylase and alpha-2-macroglobulin (A2MG), has been found between salivary and serum samples [124] . Moreover, salivary A2MG levels correlate to fasting blood glucose (R = 0.295 vs R = 0.246) or HbA 1c (R = 0.443 vs R = 0.342) better than plasma A2MG levels [125] , [126] , [127] . It is found to be up-regulated and has a detection sensitivity and specificity of 81.9% and 89.6%, respectively [126] , [127] . Hence, salivary A2MG may serve as a non-invasive marker for diabetes [125] , although a proteomics approach could be pursued.
Gestational diabetes mellitus
Up to date, although the HbA 1c test is commonly recommended for T1D and T2D diagnosis, it has not been recommended for GDM diagnosis in any guideline, including WHO [16] , [128] . In the past few years, much research has been devoted to the use of the HbA 1c test in diagnosing of GDM. However, these studies have revealed great limitations and drawbacks of the test. Many studies showed that HbA 1c levels are elevated in GDM patients compared to normal pregnant women in their second trimester [129] , [130] , [131] . However, the choice of the cut-off point in diagnosing GDM is based upon the trade-off between sensitivity and specificity. Higher cut-off values (34-40 mmol/mol) yield lower sensitivity (26.1-73.6%) but higher specificity (77.2-94.9%), while lower cut-off values (34-29 mmol/mol) yield higher sensitivity (85.0-91.1%) but lower specificity (31.8-62.0%) [129] , [130] , [131] , [132] . During their third trimester, the efficacy in diagnosing GDM using HbA 1c is low with moderate sensitivity (85.7%) and poor specificity (61.1%) [133] . As a comparison, by using OGT test, the current recommended test for GDM, the overall concordance between OGT test and HbA 1c results were poor during the third trimester of pregnancy [134] . Therefore, alternative biomarkers for the diagnosis of GDM are still required. Guo et al. found that the expressions of CD59 decreased and interleukin-1 receptor antagonist (IL1RA) increased in the urine of GDM women early in the second trimester, compared to normal pregnant women by using isobaric tags for relative and absolute quantification (iTRAQ) labelling, followed by quantitative proteomic tools, liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis and validation with enzyme-linked immunosorbent assay (ELISA) [135] . The IL1RA candidate biomarker performed more accurately when comparing to the CD9 marker, while combining them increased GDM prediction [135] .
Recently, there are many other possible protein biomarkers for diagnosing GDM, which include glycoproteins, polypeptides, immune molecules, immunosuppressant molecules, neuropeptides, hormones, enzymes and receptors. Table 8 shows a list of possible serum protein biomarkers in the diagnosis of GDM. Most of the listed biomarkers are related to insulin resistance and glucose metabolism. These include afamin, cystatin-C, soluble pro-renin receptor (s[Pro]RR), tumour necrosis factor-α (TNF-α), adiponectin, pregnancy-associate plasma protein-A (PAPP-A) and tumour necrosis factor-like weak inducer of apoptosis (TWEAK) [113] , [136] , [137] , [138] , [139] , [140] , [141] , [142] . In addition, serum cyclophilin A (CyPA) correlates positively well with C-reactive protein concentration (R = 0.599) during the first trimester of pregnancy [143] , although these findings were not via proteomics-based analysis. The discriminative potential of these biomarkers in diagnosing GDM in terms of diagnostic accuracy varies significantly. A summary of the sensitivities and specificities of serum protein biomarkers in predicting or diagnosing GDM is as in Table 9 . [144] , [145] , [146] , [147] , [148] , [149] , [150] , [151] , [152] , [153] , [154] , [155] 
Second
Afamin, cystatin-C, TNF-α, galanin Irisin, SHBG [113] , [138] , [144] , [145] , [156] , [157] , [158] , [159] , [160] Third -TWEAK [142] IL-6, Interleukin 6; hs-CRP, high-sensitivity C-reactive protein; s(Pro)RR, soluble pro-renin receptor; TNF-α, tumour necrosis factor-α; SHBG, sex hormone-binding globulin; PAPP-A, pregnancy-associate plasma protein-A; TWEAK, tumour necrosis factor-like weak inducer of apoptosis. When combining two serum proteomic biomarkers, the accuracy in predicting or diagnosing GDM increases. For example, when using the adiponectin/TNF-α ratio, a decrease is a better indicator for the diagnosis of GDM than either alone [138] . Another example is combining sex hormone-binding globulin (SHBG) and high-sensitivity C-reactive protein (hs-CRP). A combination of low SHBG and high hs-CRP levels increased the sensitivity and specificity in predicting GDM to 74.07% and 75.62%, respectively, compared to either indicator alone [148] . In contrast, glycosylated fibronectin alone gave a strong association to GDM status, whereas hs-CRP and adiponectin only showed marginal association [149] . Therefore, in this case, glycosylated fibronectin represents a promising biomarker in screening the risk of developing GDM during the first trimester of pregnancy.
Metabolomics
Metabolomics is the large-scale study of metabolites present in a system (cell, tissue, or organism) at a given set of conditions to identify out-of-normal range perturbations of metabolites. Metabolites are small molecules (<1500 Da), including amino acids, fatty acids, carbohydrates and other products associated with cellular metabolic functions [28] . The tools that are mainly associated in this study can be classified into either mass spectrometry-based or nuclear magnetic resonance (NMR)-based approaches [161] .
Type 1 diabetes mellitus
The metabolic changes in diabetic patients are different from that of healthy individuals due to the dysfunction of the insulin receptor or the production of insulin. Recently, advanced glycation end-products (AGE) in skin is found to be related to long-term glycaemic control and complications in T1D patients, and it can be measured using skin autofluorescence (sAF) [162] , [163] , [164] , [165] . It is higher in T1D children and non-white T1D patients due to elevated soluble receptor AGE (sRAGE) [163] , [164] , [166] , [167] . AGE has been found to be related to HbA 1c and fasting plasma glucose [162] , [164] , [165] , [166] , [167] ; and associated with retinopathy and albuminuria [162] , [164] . Therefore, with a metabolomics approach, sAF may serve as a non-invasive method to measure AGE as a biomarker to diagnose T1D.
Type 2 diabetes mellitus
Similar to T1D metabolomics, the metabolic changes in diabetic patients are due to insulin resistance of organs. Metabolomics analysis, coupled with tandem mass spectrometry (MS/MS) tools, works very well in identifying potential diagnostic biomarkers for T2D from many different biological human samples, including serum, saliva, skin and urine [168] , [169] . A summary of diagnostic biomarkers for T2D found in various biological samples is listed in Table 10 . 1,5-Anhydroglucitol (1,5-AG) is a stable compound in blood. Many recent studies showed that 1,5-AG levels in the sera of T2D patients rapidly decrease; and the decrease is inversely correlated to glucose level (R = −0.470) [170] , [171] , [172] . As blood glucose level increases in T2D, it inhibits the reabsorption of 1,5-AG from kidney tubules by competing with it [173] . 1,5-AG is useful in providing short-term (3-7 days) glycaemic status of an individual and is associated with early phase insulin secretion [170] , [172] . When used as a diagnostic marker, its sensitivity (92.6%) and specificity (82.3%) is higher than other glycaemic indicators [171] . Thus, it may serve as a potential diagnostic biomarker for T2D. However, it has poor diagnostic accuracy for GDM [174] .
Saliva plays an important role in oral physiology [175] . It is a complex secretion composed of mainly water and few other components, such as glucose, proteins, nitrogenous products, and electrolytes, secreted by the salivary gland [176] . Multiple biochemical alterations including levels of glucose have been shown in saliva of diabetic patients [177] , [178] . Using metabolomics approaches such as LC-MS/MS or gas chromatographytandem mass spectrometry (GC-MS/MS), 1,5-AG in saliva was found to be correlated with 1,5-AG in blood (R = 0.74), but inversely-correlated with blood glucose (R = −0.51) [168] . Just like in serum, saliva 1,5-AG provides a sensitivity of 90.3% and specificity of 78.4% when used as a diagnostic biomarker for T2D [168] . X-11315 in saliva, which was also detected in blood, is highly correlated with plasma 1,5-AG levels (R = 0.54) [168] . The biochemical identity of this metabolite is still unknown [168] . In addition, in older people, using the ultraperformance liquid chromatography-tandem mass spectrometer (UPLC-MS/MS) approach, late-onset T2D had an elevated 5′-MTA level, but lower levels of cAMP, acetylhistidine and phenylalanine in their urine samples [169] . Comparing these 4 metabolites, in urine, 5′-MTA has the greatest change in late-onset T2D than nondiabetic individuals [169] , which therefore may serve as a validated biomarker of T2D in human urine.
Another recent biological sample that could be used to diagnose T2D is breath. In breath, a high number of volatile organic compounds (VOCs) are derived from metabolic origins and are associated with one's health status and condition. VOCs can be detected using gas chromatography time-of-flight mass spectrometry (GC-TOF-MS) as a metabolomics approach [179] , [180] . It is long known that acetone is one of the products formed due to ketosis of T1D and T2D [181] , [182] . The sensitivity and specificity of breath acetone is 100% and 97.7%, respectively [183] , [184] . However, there is great difficulty in detecting acetone levels as it exists in trace amounts. The use of 1-butyl-3-methylimidazolium tetrafluoroborate and quartz crystal microbalance sensor as diagnostic tools are able to detect acetone amongst VOCs in a breath test [185] . Hence, it is an example of a current development of a non-invasive sensor for early diabetes detection. Furthermore, 13 C-enriched foods could replace 13 C-labelled glucose in the breath test for the diagnosis of pre-diabetic and T2D, as the sensitivity and specificity is about 95% in detecting carbon dioxide levels in breath [186] , [187] .
Gestational diabetes mellitus
Metabolomics is also of great diagnostic value for GDM as the early disruption of many metabolites is seen to be associated with GDM. Many GDM-specific metabolites are found mostly in blood but some are in urine using metabolomics tools such as MS-associated tools [188] , [189] . However, a number of factors such as dietary intake, daily activities and hormonal changes may affect the dynamic nature of the biofluid and hence potentially lead to result discrepancy. Thus, an alternative and stable biological sample may be better than blood and urine.
Among the metabolites, serum fatty acids and amino acids are strongly correlated with GDM [189] , [190] . Increased levels of serum even-chain saturated fatty acid (SFA) and decreased levels of serum odd-chain SFA increase the risk of GDM in pregnant women [191] . The serum amino acids in GDM patients are mainly upregulated in all three trimesters of pregnancy, but the level of amino acids is different at each trimester [190] , [192] , [193] , [194] , [195] . An amino acid, valine, is increased in the second and third trimesters of pregnancy, as well as in postpartum GDM [188] , [190] , [195] . Valine plays a role in insulin resistance by promoting fatty acid uptake to muscle [196] . The continuous increase in valine level postpartum is a risk of T2D for GDM women [193] . Other serum metabolites that are changed in GDM include acylcarnitines, sugars and alcohols, organic acids and cholesterol [190] , [193] , [197] . As for urine, an increase in urinary ethylmalonate concentration is associated with an increase in the risk of GDM, whereas a decrease in urinary adipate increases the risk of GDM early in the second trimester of pregnancy [198] . Also, the change in serotonin-related metabolites in urine improves risk prediction accuracy in GDM [188] . All these metabolite changes found in GDM serum or urine may serve as predictive or early diagnosis biomarkers for GDM. Nevertheless, the diagnostic accuracy of each of these metabolites should be studied to confirm its potential.
Besides blood and urine, hair could serve as a non-invasive biological sample. Hair is a stable specimen and provides long-term metabolic information. Recent studies have gained interest in the use of hair as a biological sample for potential metabolic biomarkers in diagnosing GDM [199] , [200] . Adipic acid is significantly higher in GDM compared to healthy pregnant women during the second trimester of pregnancy [199] . On the other hand, tryptophan and leucine are increased in GDM during the second trimester of pregnancy [200] . During the third trimester of pregnancy, tryptophan, leucine, citric acid, 3,4-oxaolidinercarboxylic acid, 2-oxovaleric acid, 3-pyridinecarboxamide and 2-oxobutyric acid are decreased in GDM, while 1-hydroxy-3-3-nonanone and 22-oxavitamine D3 are increased in GDM [200] . As hair metabolome research related to GDM is still at its infancy, more studies are required to confirm the use of metabolic changes in hair as a non-invasive metabolomic diagnostic biomarker for GDM.
Metagenomics
Metagenomics is a high-throughput gene level study recovered from environmental samples, in order to study a community of microorganisms. This allows high-resolution genomic analysis of microbes and correlation of genomes with particular functions in the environment, such as the human body [201] . A variety of sequencing tools, such as 16S rRNA sequencing, whole genome sequencing and shotgun metagenomics sequencing may be used in metagenomics studies [201] .
Type 1 diabetes mellitus
Gut microbes affect many biological functions in the body. By using 16S rRNA sequencing tool on HLA genotype-positive T1D stool samples combined with KEGG orthologues for functional characterisation, levels of gut microbe genes involved in carbohydrate metabolism, adhesions, motility, phages, prophages, sulphur metabolism and stress responses were higher in T1D, while genes involved in DNA and protein metabolism, aerobic respiration, and amino acid synthesis were higher in healthy individuals [202] , [203] . At the phylum level, more Actinobacteria, Bacteroidetes and Proteobacteria were associated with T1D, while Firmicutes, Fusobacteria, Tenericutes and Verrucomicrobia were more in healthy individuals [202] . It was also reported that the number of Actinobacteria, Bacteroidetes, and Proteobacteria were increased, while Firmicutes was reduced in the faecal samples of T1D mice carrying the diabetogenic CD8 + T cell receptor [204] .
At the genus level, by using 16S rRNA sequencing based on metagenomics linkage groups, the greatest change in the gut microbiome was seen between mucin-degrading bacteria (genera: Provotella) and short-chain fatty acids bacteria (genera: Bacteroides) [202] . Provotella spp. was found to present abundantly in healthy individuals but not in T1D patients, while Bacteroides spp. was abundant in T1D patients to compensate the loss of Provorella spp. [202] . Other bacteria such as short chain fatty acids producers (genera: Alistipes), lactate producers (genera: Lactobacillus, Lactococcus, Bifidobacterium, and Streptococcus) were more abundant in T1D patients' stools, while butyrate-producing bacteria (genera: Eubacterium, Fusobacterium, Anaerostipes, Roseburia, Subdoligranulum, and Faecalibacterium) and mucin-degrading bacteria (genera: Akkermansia) were more abundant in the stool samples of healthy individual [202] , [205] , [206] . Using shotgun metagenomic sequencing, other bacteria in addition to those previously stated were found to differ in the stool samples of T1D patients [203] . The number of long-chain triglycerides producers (genera: Blautia) and short-chain fatty acids producers (genera: Ruminococcus) were increased, while propionate producers (genera: Veillonella) was decreased in abundance in T1D patients [202] , [203] . Complete absence of Coprococcus eutactus and Dialister invisus was noted in T1D patients [203] . On the other hand, 16S rRNA sequencing showed a decrease in the abundance of Bacteroides and Ruminococcus spp. members in mice harbouring protective alleles at the T1D-associated risk loci [207] . Bacteria such as Akkermansia and Faecalibacterium spp. decreased, while Ruminococcus and Streptococcus spp. increased in prediabetic persons' stools [208] . Akkermansia spp. differed the most in prediabetic conditions [208] . In T1D, a decreased Akkermansiamuciniphila population causes increased serum endotoxin levels and islet toll-like receptor expression, as well as decreased regulation of immunity [209] .
Type 2 diabetes mellitus
Using 16S rRNA sequencing on T2D patients' stool samples combined with KEGG and eggNOG orthologues for functional characterisation at the module and pathway levels, the gut microbiota involved in membrane transport of sugars, branched-chain amino acid (BCAA) transport, methane metabolism, xenobiotics degradation and metabolism and sulphate reduction were enriched in T2D patients [210] . By contrast, there was a decrease in the levels of bacterial chemotaxis, flagellar assembly, butyrate biosynthesis and metabolism of cofactors and vitamins [210] . Some important functions, including butyrate biosynthesis and sulphate reduction, coincided with the T2D-associated bacteria identified in the metagenomic linkage group analysis. The butyrate-producing bacteria seemed to be the primary contributors to cell motility [210] .
In terms of categorisation by metagenomics linkage group, gut microbes such as the short chain fatty acids producers (genera: Bacteroides caccae) and sulphate-reducing species (genera: Desulfovibrio), were found enriched in T2D stool samples, while butyrate-producers (genera: Clostridium, Eubacterium, Faecalibacterium, and Roseburia), and mucin-degrading bacteria (genera: Akkermansia and Prevotella) were enriched in healthy patients but not the stools of T2D patients [210] , [211] , [212] . Also, Eggerthella lenta and Escherichia coli were reported to be enriched in T2D stool samples [210] . Whole genome shotgun gene sequencing, on the other hand, presented another bacterium that is less prevalent but showed changes in the stool of T2D patients are methane producers (genera: Methanobrevibacter) [212] . However, bacteria such as Clostridium, Akkermansia, and Faecalibacterium decreased, while Ruminococcus spp. increased in the stool of prediabetic individuals [208] . Clostridium and Akkermansia spp. differed the most in prediabetes [208] . Moreover, changes in gut microbes such as Bacteroides, Blautia, Alistipes and members of the phyla Firmicutes were found to be associated with obesity [212] , [213] . Akkermansia muciniphilia had been reported to be negatively correlated with body mass index, fasting blood glucose and insulin levels, but positively-correlated with riboflavin and nicotinamide adenine dinucleotide biosynthesis [212] . On the other hand, Prevotella copri is linked to the risk of glucose intolerance and T2D [214] .
Gestational diabetes mellitus
The microbiota of the oral cavity, vagina and intestine are greatly altered in GDM. GDM patients have more operational taxonomic units (OTUs) in at least two body sites compared to healthy pregnant women, and the largest changes occurred in the oral cavity with more Proteobacteria in GDM patients [215] . This indicates that a microbial shift in the maternal microbiota of different body sites could associate with GDM during pregnancy. Nevertheless, the human gut is still the most common site for microbiome imbalance in GDM patients [215] , [216] , [217] , [218] , [219] . Thus, the dysbiosis of gut microbiome may modulate the development of GDM and serve as a diagnostic biomarker for GDM.
At the phylum level, gut microbiome such as Actinobacteria, Proteobacteria and Firmicutes are taxonomic biomarkers of GDM, where Firmicutes is the most abundant phylum [219] . At the order level, Clostridiales decreases in GDM fecal samples [216] . At the genus and species level, GDM patients have increased Parabacteroides distasonis, Coprococcus comes, Bacteroides spp., Faecalibacterium spp., Prevotella spp., and unclassified Lachnospiraceae spp.; but healthy pregnant women have higher Roseburia spp., Fusobacterium spp., Haemophilus spp., Alistipes spp. (A. shahii and A. senegalensis) , and Bifidobacterium spp. (B. animalis and B. pseudocatenulatum) , as categorised by metagenomics linkage groups using whole-metagenome shotgun sequencing and 16S rRNA gene sequencing [216] , [219] .
In terms of functional composition by KEGG and eggNOG orthologues, the gut microbiome in GDM patients has a greater abundance of membrane transport, energy metabolism pathways, lipopolysaccharide, and phosphotransferase systems; while the gut microbiome in healthy pregnant women is more abundant in amino acid metabolic pathways [216] . In gestational glucose metabolism, insulin resistance and C-peptide are linked with phylum Actinobacteria and Firmicutes (such as Blautia spp.) [218] , [219] . At species level, Lachnospiraceae spp., P. distasonis, Prevotella spp., and Faecalitalea spp. affect plasma glucose level, while Alistipes spp. has no effect [216] , [219] . Bacteriodes spp. is associated with higher plasma hs-CRP but Alistipes spp. is related to lower hs-CRP [219] .
In energy metabolism, higher serum leptin is related to members of the phylum Firmicutes (Family: Lachnospiraceae and Ruminococcaceae), whereas resistin is decreased in phylum Firmicutes (Family: Ruminococcaceae) [218] . Among all the gut microbiome, members of the Bacteroides or Parabacteroides genera have the highest discriminatory power between GDM patients and healthy pregnant women [216] .
Although the pathogenesis of gut microbiome dysbiosis towards diabetes is not fully understood, but these data mainly showed lactate-and butyrate-producing bacteria in a healthy gut inducing a sufficient amount of mucin synthesis to maintain gut integrity. In contrast, non-butyrate-producing lactate-utilising bacteria (like short chain fatty acids and long-chain triglycerides producers) prevent optimal mucin synthesis, which causes diabetes. The information is useful as it may serve as an early diagnosis of diabetes prior to the clinical onset of disease. However, it is important to note that most studies of the taxonomic and functional signals detected in diabetic-control comparisons showed varying results due to geographic heterogeneity.
Conclusions
The search for diagnostic biomarkers in diabetes is rapidly expanding. Increasing efforts have been devoted to novel diabetes diagnostic biomarker discovery. However, most of the omics-based approach studies reviewed that biomarkers identified so far in T1D, T2D and GDM are mainly focused on serum samples. Nevertheless, non-invasive diagnostic biomarkers and tools have lately increased focusing on saliva, skin, breath, fecal and hair samples. Among all the omics-based biomarkers, proteomic biomarkers are identified the most in diagnosing diabetes. A summary of the strongest candidate biomarkers is shown in Table 11 . Despite much efforts, the diagnostic accuracy and clinical usefulness of many biomarkers are yet to be fully validated. On top of that, there are limited studies done on the relationship between these biomarkers, diabetes development and the ability to differentiate the different types of diabetes. Table 11 : A summary of the strongest candidate diagnostic biomarkers in diagnosing diabetes.
Omics
Types of diabetes Biomarkers
Genomics T1D HLA-DRβ1-HLA-DQα1-HLA -DQβ1 region  T2D  CDKAL1 region  GDM  CDKAL1 region   Transcriptomics  T1D  MiR-103  T2D MiR-126 GDM MiR-20a-5p
Proteomics T1D Mitochondrial translational initiation factor 3 T2D
Peroxisome proliferator-activated receptor gamma GDM Adiponectin/TNF-α ratio Metabolomics T1D soluble receptor AGE T2D 1,5-Anhydroglucitol GDM Valine Metagenomics T1D Butyrate-producing bacteria, short chain fatty acid bacteria, and mucin degrading bacteria T2D GDM T1D, Type 1 diabetes; T2D, type 2 diabetes; GDM, gestational diabetes mellitus; CDKAL1, cyclin-dependent kinase 5 regulatory subunit associated protein 1-like 1; TNF-α, tumour necrosis factor-α.
Future directions
Future research may focus more on non-invasive biomarkers as an alternative method in diagnosing diabetes, with validation on diagnostic accuracy. Furthermore, omics-based diagnostic tools to detect the various biomarkers should also be improved to be used as a standard-of-care practice. Moreover, more studies are needed to confirm the relationship of the biomarkers with diabetes pathophysiology and the potential ability in differentiating them. In order to do so, researchers could look into multi-omics approaches as they offer an opportunity to understand the flow of information that underlies disease, from the original cause of disease (genetic, environmental or developmental) to the functional consequences or relevant interactions instead of a single omics approach. Researchers should also focus on biomarkers for the transition from GDM to T2D. The potential diagnostic biomarkers stated in this article may also serve as therapeutic targets in treating diabetes.
